{"id":65699,"date":"2026-05-19T23:05:06","date_gmt":"2026-05-19T15:05:06","guid":{"rendered":"https:\/\/flcube.com\/?p=65699"},"modified":"2026-05-19T23:05:07","modified_gmt":"2026-05-19T15:05:07","slug":"boehringer-ingelheims-jascayd-nerandomilast-approved-in-japan-for-ipf-and-progressive-pulmonary-fibrosis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65699","title":{"rendered":"Boehringer Ingelheim&#8217;s JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis"},"content":{"rendered":"\n<p><strong>Boehringer Ingelheim (BI)<\/strong> announced that Japan&#8217;s <strong>Ministry of Health, Labour and Welfare (MHLW)<\/strong> has granted <strong>approval for JASCAYD (nerandomilast)<\/strong> for the treatment of <strong>adults with idiopathic pulmonary fibrosis (IPF)<\/strong> and <strong>adults with progressive pulmonary fibrosis (PPF)<\/strong>. This approval establishes nerandomilast as a <strong>globally recognized therapy<\/strong> now available in the <strong>U.S., China, UAE, and Japan<\/strong>, supported by the <strong>largest Phase 3 program<\/strong> ever conducted across IPF and PPF populations.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-approvals-amp-global-availability\">Regulatory Approvals &amp; Global Availability<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Approved Markets<\/th><th>Indications<\/th><th>Regulatory Status<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td>IPF and PPF<\/td><td>Approved<\/td><\/tr><tr><td><strong>China<\/strong><\/td><td>IPF and PPF<\/td><td>Approved<\/td><\/tr><tr><td><strong>UAE<\/strong><\/td><td>IPF and PPF<\/td><td>Approved<\/td><\/tr><tr><td><strong>Japan<\/strong><\/td><td>IPF and PPF<\/td><td>Newly approved (May 2026)<\/td><\/tr><tr><td><strong>Additional Markets<\/strong><\/td><td>Under review<\/td><td>Multiple submissions pending<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<p><strong>JASCAYD (nerandomilast)<\/strong> represents a <strong>novel therapeutic approach<\/strong> in pulmonary fibrosis:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: <strong>Oral PDE4B inhibitor<\/strong> with dual <strong>antifibrotic and immunomodulatory effects<\/strong><\/li>\n\n\n\n<li><strong>Target Specificity<\/strong>: Selective inhibition of <strong>phosphodiesterase 4B (PDE4B)<\/strong> enzyme involved in inflammatory and fibrotic pathways<\/li>\n\n\n\n<li><strong>Administration<\/strong>: Oral dosing enables convenient outpatient treatment compared to existing therapies<\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: Addresses both <strong>inflammatory drivers<\/strong> and <strong>fibrotic processes<\/strong> underlying disease progression<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pivotal-clinical-evidence\">Pivotal Clinical Evidence<\/h2>\n\n\n\n<p>The Japanese approval is supported by <strong>robust data<\/strong> from the <strong>Phase 3 FIBRONEER program<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>FIBRONEER-IPF Trial<\/strong>: Largest Phase 3 study in IPF population to date<\/li>\n\n\n\n<li><strong>FIBRONEER-ILD Trial<\/strong>: Largest Phase 3 study in PPF population to date<\/li>\n\n\n\n<li><strong>Primary Endpoint<\/strong>: Both trials demonstrated <strong>statistically significant improvement in lung function<\/strong> compared to placebo<\/li>\n\n\n\n<li><strong>Program Scale<\/strong>: Combined studies represent the <strong>most comprehensive clinical development program<\/strong> across pulmonary fibrosis indications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-unmet-medical-need\">Market Impact &amp; Unmet Medical Need<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IPF Burden<\/strong>: Affects approximately <strong>50,000 patients in Japan<\/strong>, with median survival of 3-5 years post-diagnosis<\/li>\n\n\n\n<li><strong>PPF Population<\/strong>: Significantly larger than IPF alone, encompassing <strong>multiple interstitial lung diseases<\/strong> with progressive phenotypes<\/li>\n\n\n\n<li><strong>Current Standard<\/strong>: Limited treatment options with modest efficacy and significant side effect profiles<\/li>\n\n\n\n<li><strong>Commercial Opportunity<\/strong>: Japanese pulmonary fibrosis market valued at <strong>\u00a525-30 billion<\/strong> ($170-200 million) annually<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-differentiation\">Competitive Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Indication<\/strong>: Only therapy approved for <strong>both IPF and PPF<\/strong> in Japan, providing broad market access<\/li>\n\n\n\n<li><strong>Oral Convenience<\/strong>: Superior administration profile compared to existing antifibrotic therapies requiring multiple daily doses<\/li>\n\n\n\n<li><strong>Mechanistic Innovation<\/strong>: First <strong>PDE4B-selective inhibitor<\/strong> approved for pulmonary fibrosis, offering novel mechanism of action<\/li>\n\n\n\n<li><strong>Global Consistency<\/strong>: Same regulatory outcome across major markets validates <strong>robust clinical data package<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-for-boehringer-ingelheim\">Strategic Implications for Boehringer Ingelheim<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Respiratory Franchise Expansion<\/strong>: Strengthens BI&#8217;s position as a <strong>global leader in respiratory therapeutics<\/strong><\/li>\n\n\n\n<li><strong>Japan Market Leadership<\/strong>: Establishes early foothold in Japanese pulmonary fibrosis market ahead of competitors<\/li>\n\n\n\n<li><strong>Revenue Diversification<\/strong>: Adds high-value specialty medicine to BI&#8217;s <strong>Japanese commercial portfolio<\/strong><\/li>\n\n\n\n<li><strong>Pipeline Validation<\/strong>: Success supports development of additional <strong>PDE4B-targeted therapies<\/strong> in inflammatory conditions<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-advantages-amp-patient-benefits\">Clinical Advantages &amp; Patient Benefits<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lung Function Preservation<\/strong>: Demonstrated ability to <strong>slow disease progression<\/strong> and maintain pulmonary function<\/li>\n\n\n\n<li><strong>Tolerability Profile<\/strong>: PDE4B selectivity may offer <strong>improved safety<\/strong> compared to pan-PDE4 inhibitors<\/li>\n\n\n\n<li><strong>Quality of Life<\/strong>: Oral once-daily dosing improves <strong>treatment adherence<\/strong> and reduces pill burden<\/li>\n\n\n\n<li><strong>Broad Applicability<\/strong>: Single therapy addresses <strong>multiple progressive fibrotic lung diseases<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-access-amp-reimbursement\">Market Access &amp; Reimbursement<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pricing Premium<\/strong>: Orphan-like status in Japan supports <strong>premium pricing<\/strong> for innovative antifibrotic therapy<\/li>\n\n\n\n<li><strong>Reimbursement Pathway<\/strong>: Established precedents for pulmonary fibrosis therapies facilitate <strong>rapid coverage decisions<\/strong><\/li>\n\n\n\n<li><strong>Diagnostic Infrastructure<\/strong>: Growing awareness of PPF diagnosis expands <strong>addressable patient population<\/strong><\/li>\n\n\n\n<li><strong>Physician Education<\/strong>: Comprehensive launch program to support <strong>appropriate patient identification<\/strong> and treatment initiation<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial expectations for JASCAYD. Actual results may differ due to risks including market adoption rates, competitive dynamics, pricing pressures, and healthcare policy changes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boehringer Ingelheim (BI) announced that Japan&#8217;s Ministry of Health, Labour and Welfare (MHLW) has granted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":65702,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[390,15],"class_list":["post-65699","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-boehringer-ingelheim","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Boehringer Ingelheim&#039;s JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Boehringer Ingelheim (BI) announced that Japan&#039;s Ministry of Health, Labour and Welfare (MHLW) has granted approval for JASCAYD (nerandomilast) for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF). This approval establishes nerandomilast as a globally recognized therapy now available in the U.S., China, UAE, and Japan, supported by the largest Phase 3 program ever conducted across IPF and PPF populations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65699\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer Ingelheim&#039;s JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis\" \/>\n<meta property=\"og:description\" content=\"Boehringer Ingelheim (BI) announced that Japan&#039;s Ministry of Health, Labour and Welfare (MHLW) has granted approval for JASCAYD (nerandomilast) for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF). This approval establishes nerandomilast as a globally recognized therapy now available in the U.S., China, UAE, and Japan, supported by the largest Phase 3 program ever conducted across IPF and PPF populations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65699\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-19T15:05:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-19T15:05:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1908.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65699#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65699\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boehringer Ingelheim&#8217;s JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis\",\"datePublished\":\"2026-05-19T15:05:06+00:00\",\"dateModified\":\"2026-05-19T15:05:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65699\"},\"wordCount\":580,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65699#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1908.webp\",\"keywords\":[\"Boehringer Ingelheim\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65699#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65699\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65699\",\"name\":\"Boehringer Ingelheim's JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65699#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65699#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1908.webp\",\"datePublished\":\"2026-05-19T15:05:06+00:00\",\"dateModified\":\"2026-05-19T15:05:07+00:00\",\"description\":\"Boehringer Ingelheim (BI) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted approval for JASCAYD (nerandomilast) for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF). This approval establishes nerandomilast as a globally recognized therapy now available in the U.S., China, UAE, and Japan, supported by the largest Phase 3 program ever conducted across IPF and PPF populations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65699#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65699\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65699#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1908.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1908.webp\",\"width\":1080,\"height\":608,\"caption\":\"Boehringer Ingelheim's JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65699#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer Ingelheim&#8217;s JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim's JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis - Insight, China&#039;s Pharmaceutical Industry","description":"Boehringer Ingelheim (BI) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted approval for JASCAYD (nerandomilast) for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF). This approval establishes nerandomilast as a globally recognized therapy now available in the U.S., China, UAE, and Japan, supported by the largest Phase 3 program ever conducted across IPF and PPF populations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65699","og_locale":"en_US","og_type":"article","og_title":"Boehringer Ingelheim's JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis","og_description":"Boehringer Ingelheim (BI) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted approval for JASCAYD (nerandomilast) for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF). This approval establishes nerandomilast as a globally recognized therapy now available in the U.S., China, UAE, and Japan, supported by the largest Phase 3 program ever conducted across IPF and PPF populations.","og_url":"https:\/\/flcube.com\/?p=65699","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-19T15:05:06+00:00","article_modified_time":"2026-05-19T15:05:07+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1908.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65699#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65699"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boehringer Ingelheim&#8217;s JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis","datePublished":"2026-05-19T15:05:06+00:00","dateModified":"2026-05-19T15:05:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65699"},"wordCount":580,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=65699#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1908.webp","keywords":["Boehringer Ingelheim","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65699#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65699","url":"https:\/\/flcube.com\/?p=65699","name":"Boehringer Ingelheim's JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=65699#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=65699#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1908.webp","datePublished":"2026-05-19T15:05:06+00:00","dateModified":"2026-05-19T15:05:07+00:00","description":"Boehringer Ingelheim (BI) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted approval for JASCAYD (nerandomilast) for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF). This approval establishes nerandomilast as a globally recognized therapy now available in the U.S., China, UAE, and Japan, supported by the largest Phase 3 program ever conducted across IPF and PPF populations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65699#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65699"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=65699#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1908.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1908.webp","width":1080,"height":608,"caption":"Boehringer Ingelheim's JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65699#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim&#8217;s JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1908.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65699"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65699\/revisions"}],"predecessor-version":[{"id":65703,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65699\/revisions\/65703"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/65702"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}